Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Castle Biosciences, Inc. - Common stock
(NQ:
CSTL
)
41.09
+0.32 (+0.78%)
Streaming Delayed Price
Updated: 9:31 AM EST, Jan 15, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Castle Biosciences, Inc. - Common stock
< Previous
1
2
3
4
5
6
7
8
9
...
13
14
Next >
Castle Biosciences to Present at the Leerink Partners Healthcare Crossroads Conference
May 15, 2024
From
Castle Biosciences Inc.
Via
Business Wire
Castle Biosciences Expands Evidence Supporting the Performance of its TissueCypher® Barrett’s Esophagus Test in Predicting Future Development of Esophageal Cancer Through Multiple Data Presentations at DDW 2024
May 14, 2024
From
Castle Biosciences Inc.
Via
Business Wire
Castle Biosciences’ IDgenetix® Test Receives 2024 MedTech Breakthrough Award for “Best Overall Mental Health Solution”
May 10, 2024
From
Castle Biosciences Inc.
Via
Business Wire
Recap: Castle Biosciences Q4 Earnings
↗
February 28, 2024
Via
Benzinga
Earnings Preview For Castle Biosciences
↗
February 27, 2024
Via
Benzinga
Largest Prospective Study to Date Further Supports Performance of DecisionDx®-UM for Metastatic Risk Stratification in Uveal Melanoma and Utility of PRAME Biomarker for Refining Risk When Considered with DecisionDx-UM Class Result
May 08, 2024
From
Castle Biosciences Inc.
Via
Business Wire
DecisionDx®-SCC Significantly Improves Prediction Accuracy of Metastatic Events after Mohs Surgery in New Study of Patients with High-Risk Cutaneous Squamous Cell Carcinoma Tumors of the Head and Neck
May 03, 2024
From
Castle Biosciences Inc.
Via
Business Wire
CSTL Stock Earnings: Castle Biosciences Beats EPS, Beats Revenue for Q1 2024
↗
May 02, 2024
CSTL stock results show that Castle Biosciences beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.
Via
InvestorPlace
Castle Biosciences Reports First Quarter 2024 Results
May 02, 2024
From
Castle Biosciences Inc.
Via
Business Wire
Castle Biosciences Kicks off Skin Cancer Awareness Month with a Ribbon Cutting to Celebrate the City of Friendswood’s Designation as a Sun Safe Leadership Model City by IMPACT Melanoma
April 30, 2024
From
Castle Biosciences Inc.
Via
Business Wire
Castle Biosciences to Release First Quarter 2024 Financial Results and Host Conference Call on Thursday, May 2, 2024
April 11, 2024
From
Castle Biosciences Inc.
Via
Business Wire
Castle Biosciences Celebrates Esophageal Cancer Awareness Month through Advocacy and Educational Collaborations
April 10, 2024
From
Castle Biosciences Inc.
Via
Business Wire
Castle Biosciences’ Chief Financial Officer Frank Stokes Recognized as a Top CFO of Houston for Second Consecutive Year
April 10, 2024
From
Castle Biosciences Inc.
Via
Business Wire
Presentations at EADO Highlight Potential Impact of Castle Biosciences’ DecisionDx®-Melanoma and DecisionDx®-SCC Tests on the Management of Patients with Skin Cancer
April 04, 2024
From
Castle Biosciences Inc.
Via
Business Wire
Castle Biosciences to Present at the 23rd Annual Needham Virtual Healthcare Conference
April 02, 2024
From
Castle Biosciences Inc.
Via
Business Wire
Castle Biosciences Announces Updates to its Board of Directors
March 27, 2024
From
Castle Biosciences Inc.
Via
Business Wire
Castle Biosciences Earns a Top Workplaces USA Award for the Third Consecutive Year
March 25, 2024
From
Castle Biosciences Inc.
Via
Business Wire
Long-term Outcomes Data Shared at SSO 2024 Show That Patients with a Low-Risk DecisionDx®-Melanoma Test Result Were Recurrence Free at Three Years, Including Those Who Utilized the Test to Help Guide the Decision to Avoid an SLNB
March 22, 2024
From
Castle Biosciences Inc.
Via
Business Wire
Leading Squamous Cell Carcinoma Practitioners Publish Consensus Guidelines Integrating DecisionDx®-SCC into a Clinical Workflow to Improve Decision-Making Regarding the Use of Adjuvant Radiation Therapy
March 19, 2024
From
Castle Biosciences Inc.
Via
Business Wire
New Study Shows that the Drug-Drug Interactions and Lifestyle Factors Provided by Castle Biosciences’ IDgenetix® Test Significantly Improve Medication Recommendations Over Drug-Gene Interactions Alone for Patients 65 and Older
March 15, 2024
From
Castle Biosciences Inc.
Via
Business Wire
Castle Biosciences to Present at the KeyBanc Capital Markets Virtual Life Sciences & MedTech Investor Forum
March 12, 2024
From
Castle Biosciences Inc.
Via
Business Wire
Castle Biosciences to Present New Data Highlighting the Clinical Value of its Dermatologic Tests for Patients with Skin Cancer at the 2024 American Academy of Dermatology (AAD) Annual Meeting
March 08, 2024
From
Castle Biosciences Inc.
Via
Business Wire
In Novel Cohort, New Data Confirms DecisionDx®-SCC Provides Significant, Independent and Clinically Actionable Risk-Stratification of Patients, Including in Various High-Risk Subgroups
March 07, 2024
From
Castle Biosciences Inc.
Via
Business Wire
12 Health Care Stocks Moving In Thursday's Intraday Session
↗
February 29, 2024
Via
Benzinga
Castle Biosciences Reports Fourth Quarter and Full-Year 2023 Results
February 28, 2024
From
Castle Biosciences Inc.
Via
Business Wire
Why Butterfly Network Shares Are Trading Lower By 22%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
↗
February 29, 2024
Shares of Butterfly Network, Inc. (NASDAQ: BFLY) fell sharply during Thursday’s session after the company reported mixed fourth-quarter financial results.
Via
Benzinga
Study Finds DecisionDx®-Melanoma Significantly Improves the Risk Stratification of Patients with Stage I Melanoma Compared to American Joint Committee on Cancer 8th Edition Staging
February 26, 2024
From
Castle Biosciences Inc.
Via
Business Wire
Castle Biosciences to Release Fourth Quarter and Full-Year 2023 Financial Results and Host Conference Call on Wednesday, Feb. 28, 2024
February 07, 2024
From
Castle Biosciences Inc.
Via
Business Wire
New Study Highlights Significant Potential Medicare Savings Through Use of Castle Biosciences’ DecisionDx®-SCC Test to Guide Adjuvant Radiation Therapy Decisions in Patients with Cutaneous Squamous Cell Carcinoma
January 18, 2024
From
Castle Biosciences Inc.
Via
Business Wire
Castle Biosciences Presents Data Supporting the Utility of Its Tests in the Clinical Care of Patients with Skin Cancers at the 2024 Winter Clinical Dermatology Conference - Hawaii®
January 14, 2024
From
Castle Biosciences Inc.
Via
Business Wire
< Previous
1
2
3
4
5
6
7
8
9
...
13
14
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
